FibroGen, Inc. (NASDAQ:FGEN) Short Interest Update

FibroGen, Inc. (NASDAQ:FGEN) saw a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 5,190,000 shares, a decrease of 6.1% from the March 15th total of 5,530,000 shares. Approximately 5.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,740,000 shares, the short-interest ratio is currently 1.9 days.

Insider Activity at FibroGen

In related news, CEO Thane Wettig acquired 50,000 shares of the firm’s stock in a transaction on Thursday, March 7th. The shares were acquired at an average cost of $1.91 per share, for a total transaction of $95,500.00. Following the completion of the transaction, the chief executive officer now directly owns 470,178 shares in the company, valued at approximately $898,039.98. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 2.39% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On FibroGen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Altshuler Shaham Ltd purchased a new position in FibroGen in the 4th quarter worth $28,000. Wexford Capital LP purchased a new position in shares of FibroGen during the 4th quarter valued at about $29,000. Royal Bank of Canada raised its stake in shares of FibroGen by 45.3% during the 3rd quarter. Royal Bank of Canada now owns 2,314 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 721 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in shares of FibroGen during the 3rd quarter valued at about $37,000. Finally, Quantbot Technologies LP purchased a new position in shares of FibroGen during the 2nd quarter valued at about $39,000. Hedge funds and other institutional investors own 72.71% of the company’s stock.

Analysts Set New Price Targets

Separately, William Blair reiterated a “market perform” rating on shares of FibroGen in a report on Tuesday, February 27th. One analyst has rated the stock with a sell rating and four have issued a hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $17.00.

FibroGen Stock Down 0.8 %

Shares of FibroGen stock traded down $0.01 during trading on Tuesday, reaching $1.30. The company’s stock had a trading volume of 863,690 shares, compared to its average volume of 2,561,018. The company has a market cap of $128.40 million, a price-to-earnings ratio of -0.44 and a beta of 0.70. FibroGen has a 1-year low of $0.33 and a 1-year high of $20.90. The company has a 50-day simple moving average of $2.01 and a two-hundred day simple moving average of $1.19.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.15). The firm had revenue of $27.14 million during the quarter, compared to analysts’ expectations of $40.00 million. As a group, analysts anticipate that FibroGen will post -1.09 earnings per share for the current year.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.